Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AET
Aetna Inc
AET
|
+$175M |
| 2 |
Parker-Hannifin
PH
|
+$161M |
| 3 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$149M |
| 4 |
McDonald's
MCD
|
+$138M |
| 5 |
Bank of America
BAC
|
+$135M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
American Express
AXP
|
+$253M |
| 2 |
Meta Platforms (Facebook)
META
|
+$193M |
| 3 |
Lowe's Companies
LOW
|
+$193M |
| 4 |
CME Group
CME
|
+$179M |
| 5 |
Apple
AAPL
|
+$179M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 20.85% |
| 2 | Consumer Discretionary | 12.64% |
| 3 | Healthcare | 10.98% |
| 4 | Real Estate | 6.88% |
| 5 | Industrials | 6.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1801
Hackett Group
HCKT
$276M
| $260K | ﹤0.01% |
16,548
-15
| -0.1% | -$233 |
|
|
BGG
1802
DELISTED
Briggs & Stratton Corp.
BGG
| $260K | ﹤0.01% |
+10,229
| New | +$251K |
|
1803
Trex
TREX
$4.82B
| $259K | ﹤0.01% |
+9,540
| New | +$243K |
|
1804
Atlantic Union Bankshares
AUB
$5.84B
| $256K | ﹤0.01% |
+7,085
| New | +$253K |
|
1805
Fate Therapeutics
FATE
$292M
| $256K | ﹤0.01% |
41,909
+30,311
| +261% | +$135K |
|
|
OTIC
1806
DELISTED
Otonomy, Inc.
OTIC
| $256K | ﹤0.01% |
46,100
-500
| -1% | -$2.17K |
|
|
ARAV
1807
DELISTED
Aravive, Inc. Common Stock
ARAV
| $254K | ﹤0.01% |
19,241
-8,382
| -30% | -$108K |
|
|
GNCA
1808
DELISTED
Genocea Biosciences, Inc.
GNCA
| $254K | ﹤0.01% |
27,336
+13,788
| +102% | +$139K |
|
1809
Bio-Rad Laboratories Class A
BIO
$10.2B
| $253K | ﹤0.01% |
+1,058
| New | +$256K |
|
1810
Graco
GGG
$13B
| $253K | ﹤0.01% |
+5,587
| New | +$242K |
|
1811
Mueller Water Products
MWA
$3.93B
| $253K | ﹤0.01% |
20,165
+6,442
| +47% | +$79.5K |
|
1812
Accenture
ACN
$114B
| $252K | ﹤0.01% |
+1,649
| New | +$239K |
|
1813
Oppenheimer Holdings
OPY
$1.24B
| $252K | ﹤0.01% |
+9,400
| New | +$221K |
|
1814
Federal Signal
FSS
$7.31B
| $251K | ﹤0.01% |
12,473
-11,392
| -48% | -$239K |
|
1815
Guidewire Software
GWRE
$16B
| $251K | ﹤0.01% |
3,380
-17,621
| -84% | -$1.36M |
|
1816
The Bancorp
TBBK
$2.72B
| $251K | ﹤0.01% |
25,453
+14,853
| +140% | +$136K |
|
|
EXPR
1817
DELISTED
Express, Inc.
EXPR
| $251K | ﹤0.01% |
+1,238
| New | +$203K |
|
1818
Haverty Furniture Companies
HVT
$430M
| $249K | ﹤0.01% |
10,989
-2,702
| -20% | -$65.1K |
|
1819
Oceaneering
OII
$5.02B
| $249K | ﹤0.01% |
+11,785
| New | +$251K |
|
1820
Natural Health Trends
NHTC
$15M
| $247K | ﹤0.01% |
16,259
+6,410
| +65% | +$121K |
|
1821
Cartesian Therapeutics
RNAC
$304M
| $245K | ﹤0.01% |
+832
| New | +$364K |
|
|
ACHN
1822
DELISTED
Achillion Pharmaceuticals
ACHN
| $245K | ﹤0.01% |
84,923
+66,731
| +367% | +$242K |
|
1823
AAR Corp
AIR
$5.42B
| $243K | ﹤0.01% |
+6,195
| New | +$249K |
|
|
CCMP
1824
DELISTED
CMC Materials, Inc. Common Stock
CCMP
| $243K | ﹤0.01% |
2,588
-9,790
| -79% | -$902K |
|
|
AKRX
1825
DELISTED
Akorn Inc
AKRX
| $243K | ﹤0.01% |
7,526
-2,341
| -24% | -$76.8K |
|
Similar funds
Dmitry Balyasny's Q4 2017 Portfolio in Review
As of Q4 2017, Dmitry Balyasny held 2,554 positions worth $32B, up 25% from $25.5B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Dmitry Balyasny deployed $4.77B of net new capital in Q4 2017, opening 720 new positions and adding to 686 existing holdings. Its largest new stake was iShares iBoxx $ High Yield Corporate Bond ETF: 1,700,000 shares worth $148M.
By sector, the portfolio is most concentrated in Financials at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was American Express, an estimated $253M trimmed.
- Dmitry Balyasny's largest Q4 2017 buy was iShares iBoxx $ High Yield Corporate Bond ETF: 1,700,000 shares worth $148M.
- Dmitry Balyasny added most to Aetna Inc in Q4 2017, an estimated $175M increase.
- Dmitry Balyasny's biggest Q4 2017 reduction was American Express, cutting an estimated $253M.
- Dmitry Balyasny fully exited Range Resources in Q4 2017, selling an estimated $104M.
- Dmitry Balyasny's ten largest holdings make up 11% of its $32B portfolio in Q4 2017.
- Dmitry Balyasny opened 720 new positions and closed 529 in Q4 2017.
- Dmitry Balyasny's portfolio value rose 25% quarter-over-quarter to $32B.
Based on Balyasny Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.